Parmar MK - Search Results

1

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Royston P, Parmar MK. Royston P, et al. Among authors: parmar mk. BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152. BMC Med Res Methodol. 2013. PMID: 24314264 Free PMC article.

2

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Royston P, Parmar MK. Royston P, et al. Among authors: parmar mk. Stat Med. 2002 Aug 15;21(15):2175-97. doi: 10.1002/sim.1203. Stat Med. 2002. PMID: 12210632

3

Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.

Royston P, Parmar MK, Qian W. Royston P, et al. Among authors: parmar mk. Stat Med. 2003 Jul 30;22(14):2239-56. doi: 10.1002/sim.1430. Stat Med. 2003. PMID: 12854091

4

Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer.

Royston P, Parmar MK, Sylvester R. Royston P, et al. Among authors: parmar mk. Stat Med. 2004 Mar 30;23(6):907-26. doi: 10.1002/sim.1691. Stat Med. 2004. PMID: 15027080

5

Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.

Royston P, Parmar MK, Altman DG. Royston P, et al. Among authors: parmar mk. J Natl Cancer Inst. 2008 Jan 16;100(2):92-7. doi: 10.1093/jnci/djm265. Epub 2008 Jan 8. J Natl Cancer Inst. 2008. PMID: 18182621 Clinical Trial.

6

Speeding up the evaluation of new agents in cancer.

Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Parmar MK, et al. J Natl Cancer Inst. 2008 Sep 3;100(17):1204-14. doi: 10.1093/jnci/djn267. Epub 2008 Aug 26. J Natl Cancer Inst. 2008. PMID: 18728279 Free PMC article.

7

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. J Clin Oncol. 2008 Dec 10;26(35):5802-12. doi: 10.1200/JCO.2008.16.4368. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001332 Free PMC article. Review.

8

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P. Sydes MR, et al. Among authors: parmar mk. Trials. 2009 Jun 11;10:39. doi: 10.1186/1745-6215-10-39. Trials. 2009. PMID: 19519885 Free PMC article. Clinical Trial.

9

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Gore ME, et al. Among authors: parmar mk. Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10. Lancet. 2010. PMID: 20153039 Free PMC article. Clinical Trial.

10

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.

Royston P, Barthel FM, Parmar MK, Choodari-Oskooei B, Isham V. Royston P, et al. Among authors: parmar mk. Trials. 2011 Mar 18;12:81. doi: 10.1186/1745-6215-12-81. Trials. 2011. PMID: 21418571 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page